Release Date: 9/16/2024
Expiration date: 9/16/2025
Target Audience
The intended audience for this activity includes cardiologists, primary care providers, and other healthcare professionals (including pharmacists, NPs, PAs, and nurses) in the cardiology and primary care settings.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Outline a strategy for the identification and diagnosis of patients with HF early in disease progression.
- Develop strategies for effective patient education, counseling, and shared decision making about HF diagnosis and management.
- Formulate individualized, patient-centered, comprehensive treatment plans for patients with HF.
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Credit being awarded: 0.25 ANCC contact hours
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 0.25 contact hour.
Physician Associate
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until Expiration Date 9/16/2025. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.25 contact hour(s) (which includes 0 hour(s) of pharmacology).
Commercial Support
This activity is supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Faculty
Barry Greenberg, MD
Distinguished Professor of Medicine
Director, Advanced Heart Failure Treatment Program
UCSD Medical Center
San Diego, CA
Barry H. Greenberg, MD, is Distinguished Professor of Medicine and Director of the Advanced Heart Failure Treatment Program at the University of California, San Diego (UCSD). He earned a medical degree from the State University of New York Upstate Medical University College of Medicine in Syracuse and completed his internship at George Washington University Hospital and residency in internal medicine at Yale-New Haven Hospital. Following research training at the Lipid Metabolism Branch of the National Heart, Lung, and Blood Institute in Bethesda, Maryland, he completed a fellowship in cardiology at UCSF. He then joined the faculty of Oregon Health Sciences University School of Medicine. Prior to arriving to his present position at UCSD, he was visiting professor in residence at the Royal Postgraduate Medical School in London and at the Laboratoire de Médicine Expérimentale of the Collège de France in Paris.
Dr. Greenberg’s research focuses on understanding mechanisms of cardiac dysfunction and developing new heart failure therapies. Over the past 3 decades he has served on the executive steering committees and Data Safety Monitoring Boards (DSMBs) of numerous multicenter heart failure trials. Dr. Greenberg directs a basic science laboratory that studies the molecular basis of cardiac remodeling and myocardial fibrosis. Recent clinical research activities have focused on using machine learning to develop algorithms for predicting risk of clinical events in patients with heart failure and gene therapy for treating various forms of cardiovascular disease. Dr. Greenberg has published extensively in top-tiered medical journals throughout his career.
Dr. Greenberg is co-editor of Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management, the first comprehensive text in this field, now in its 3rd edition and is editor of Myocardial Remodeling: Mechanisms and Treatment and Management of Heart Failure. He has served on the editorial board of numerous cardiology journals and is currently deputy editor of the European Journal of Heart Failure and Guest Editor-in-Chief of JACC: HF. He also is the Founder and serves as Program Director for the twice-yearly San Diego Heart Failure Symposium, which recently completed its 30th session.
Dr. Greenberg is a founding member and past President of the Heart Failure Society of America (HFSA). He chaired the initial HFSA Heart Failure Board Review and over the years has chaired numerous HFSA Committees as well as the Strategic Development initiative for the Society in 2010 and the Journal of Cardiac Failure Task Force in 2020.
Dr. Greenberg has been selected for many years as one of the “Best Doctors in America” and “Best Doctors in San Diego.” In recognition of accomplishments over the course of his career Dr. Greenberg received the HFSA’s Lifetime Achievement Award in 2017. In recognition of his accomplishments, the mayor of San Diego proclaimed July 19, 2024 as “Dr. Barry H. Greenberg Day” in the city.
Faculty Disclosures
Barry Greenberg, MD has disclosed the following relevant financial relationships:
Consultant: Affinia, Akero, Anthemm Astellas,Axon, Boerhinger Ingelheim, Bristol Myers Squibb, Cellular Dynamics, Corvia, Cytokinetics, Duke, EBR Systems, EcoR1, Faraday, Impulse Dynamics, Intellia, Inventiva, Ionis, Jaan, Maxwell, Merck, Momentum, Secretome, SummaCor, Tenaya, Univ of Virginia, Viking, Windtree; Researcher: Rocket Pharma
AKH Staff and Planners
- Lynne Kolton Schneider, PhD, Medical Writer: has no financial relationships to disclose.
- Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
- Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
- Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education and Operations: has no financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with “Opt Out” in the subject line.
